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With current success rates of confirmatory studies being only around 50%, new 
approaches to drug development are paramount. Many trials fail simply because 
ineffective treatments are identified too late. In this paper, we discuss the utility of 
multi-arm studies with treatment selection as a potential strategy that can reduce the 
high attrition rate. We illustrate the large gains in efficiency that are possible based 
on an example in Alzheimer’s disease while outlining the additional challenges that 
need to be overcome to implement such studies.
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The development of medicinal products and 
health technologies is time consuming and 
very costly. In the context of pharmaceutical 
products, for example, it is estimated that the 
development of a novel item takes 10–15 years 
and costs several hundred million pounds on 
average [1]. Among the largest contributors to 
both time and cost are confirmatory (Phase III) 
clinical trials that often involve thousands of 
patients with follow-up period frequently last-
ing years [2]. In recent years, however, around 
50% of confirmatory clinical trials have failed 
to show a beneficial effect or been rejected at 
regulatory submission [3] resulting in a large 
number of participants in these trials being 
exposed to an ineffective or even harmful treat-
ment while at the same time costing substan-
tial amounts of money. The situation within 
Phase II studies is even worse with only 18% of 
these studies progressing a drug candidate into 
Phase III trials [4]. As a result of these shock-
ingly high failure rates, alternative approaches 
to drug development are being explored. In 
this paper, we describe the advantages and 
additional complications of multi-arm studies 
that select/drop treatments during the conduct 
of the study. We begin with a description of 
the designs followed by relevant additional 
(practical) aspects that need to be considered 
before embarking on such a design. We then 
provide an illustrative example highlighting 
the efficiency gained by these approaches on 
the basis of trials in Alzheimer’s disease before 
we finish with some general conclusions.
An overview of different types of 
multi-arm studies
Multi-arm studies
A multi-arm study is a study which compares 
several experimental treatments against a com-
mon control group. An immediate advantage 
of such an approach over separate two-arm 
studies is that only a single control group is 
used. As a consequence, a patient’s chance to 
receive an experimental treatment is increased 
which has been argued could help with recruit-
ing patients to such studies [5,6]. Additionally, 
such studies allow a fair, contemporary com-
parison of different experimental treatments 
as the comparisons are made against the same 
control group and under a single protocol so 
that relevant features of the study, such as 
inclusion/exclusion criteria, are the same.
Multi-arm studies with treatment 
selection
One of the drawbacks of traditional 
two-armed studies is that they do not allow 
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Figure 1. A multi-arm study which selects all promising 
treatments at interim analysis. Three analyses are 
planned for a study with four experimental treatments 
versus control. At the first interim analysis, treatments 
1 and 3 are dropped from the study as they are below 
the futility threshold. At the second interim analysis, 
the second test statistic exceeds the upper bound so 
that superiority of treatment 2 over control can be 
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for early conclusions (for better or for worse) about the 
treatment. To overcome this, group-sequential designs 
that allow the study to stop early, either because the 
evidence is already sufficient to claim superiority of the 
treatment over control or because it is unlikely to reach 
such a claim, have been developed [7,8] and are now 
routinely used in practice.
In the same spirit, multi-arm studies can be made 
more efficient by adding interim analyses that allow 
early stopping because the evidence collected is already 
sufficient to conclude that one or more treatments 
is superior to control or to stop because none of the 
experimental treatments looks sufficiently promising. 
Additionally, interim analysis can be used to select 
which treatment(s) warrant further experimentation. 
Typical selection rules used select the best perform-
ing or the k-best treatments [9,10], select any treatments 
that are close to the best performing one [11] or select 
any treatment that looks promising [12,13]. Figure 1 
shows an example of such a design where all promis-
ing treatments continue in the study. In this example, 
two interim analyses and a final analysis are planned. 
After sufficient patients have been recruited for the first 
interim analysis, test statistics comparing each experi-
mental treatment to control are found. In the ficti-
tious example, two of the statistics, corresponding to 
experimental treatments 1 and 3, fall below the lower 
bound indicating that not further experimentation is 
warranted on these treatments and consequently these 
arms are dropped from the study. The remaining two 
test statistics, corresponding to treatments 2 and 4, 
are above the lower threshold but not above the upper 
bound. Therefore, additional information is required 
on these arms (plus control) to reach a definite conclu-
sion. More patients are consequently recruited to these 
treatments and control. At the second interim analy-
sis, the test statistic comparing experimental treatment 
2 to control exceeds the upper boundary and hence 
superiority of treatment 2 over control can be claimed 
and the trial can be stopped.
Because treatments are removed from consideration 
early and the trial can be stopped before the maxi-
mum number of patients are recruited, the required 
sample size of such studies will typically be smaller 
than a multi-arm study without treatment selection. It 
is, however, possible that the realized sample size is in 
fact larger than a multi-arm study without selection. 
In particular, in the unlikely case that no treatment 
arm can be dropped early and no early claim of supe-
riority is possible, the sample size will be larger. This 
is because allowing for early claim of superiority also 
gives additional opportunities to wrongly make such a 
claim. To counteract such mistakes and to ensure that 
the overall type I error of the procedure is controlled, 
more stringent critical values than the ones utilized for 
multi-arm studies are required. The impact of allowing 
arms to be dropped on the other hand is an increase in 
type II error if the sample size is kept the same.
To design a multi-arm study with treatment selec-
tion, two different statistical approaches can be utilized. 
The so called ‘pre-planned’ adaptive designs [9–10,12,14], 
which are extensions of group-sequential methods, 
require specification of how treatments will be selected 
(e.g., select the best treatment or any treatment surpass-
ing a predetermined threshold) while ‘fully flexible’ 
adaptive designs [15,16] do not require such pre-specifi-
cation. The cost for the additional flexibility of the lat-
ter approach is a potential loss in efficiency (typically 
power is lowered by a few% [17]). In either case, we 
believe that it is paramount that the overall type-I error 
is controlled [18]. Adding additional treatments would 
otherwise increase the change of finding an effect (even 
when all are truly ineffective). As a consequence in a 
trial without overall type-I-error control, one could sim-
ply include numerous doses of the same treatment in a 
study to be almost certain to show that the treatment 
has an effect. In current practice, overall type-I-error 
control is, however, not always adhered to [19].
Besides the added efficiency that will be illustrated 
below, a further advantage of a multi-arm study with 
treatment selection, illustrated in Figure 2, is that 
one can use an interim analysis to mark the end of 
Phase II and beginning of Phase III thereby allowing 
a seamless Phase II/III study which removes the white 
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Figure 2. Traditional development versus one based on a multi-arm design. (A) Traditional ‘sequential’ 
development process; and (B) a multi-arm design with treatment selection. In both, three novel treatments (T1, 
T2 and T3) are evaluated against control and only treatment 2 is chosen for confirmation in Phase III. In (A) each 
treatment is compared with control in separate trials, while in (B) only one control group serves for all treatments. 
C: Control.
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space between the phases. Although this may not 
always be desirable [20], it can reduce the time of drug 
development notably.
Adaptive multi-arm studies with treatment 
selection
When preforming an interim analysis for treatment 
selection, it is natural to also consider other adapta-
tions. Most commonly sample size reassessment is of 
interest. Such an adaptation uses the accumulated trial 
data to verify assumptions made about factors of the 
study and potentially adjusts the sample size required 
based on these new estimates. Typically, a factor that 
is not of primary interest (e.g., variability of the end 
point) is estimated based on the accumulated trial data 
and if the estimate deviates from the value assumed 
on initiation of the study, the new estimate is used to 
update the sample size required.
Including such additional modifications in the study 
are straightforward if fully flexible designs are used. 
For pre-planned adaptive designs, the conditional error 
approach [21,22] can be used to incorporate such additional 
adaptations. Using a pre-planned design and making it 
flexible is, however, only advisable when such adaptations 
are unplanned as a fully flexible design will typically 
be more efficient otherwise [23]. For an easy to follow 
overview of fully flexible adaptive design ideas, see [24].
An example of a multi-arm study with 
treatment selection
In the above section, we have described the general 
concept of a multi-arm study with treatment selection 
and argued that they are an efficient way to investigate 
several different treatments against a common control 
group. In this section, we will give a numerical illustra-
tion of the gains possible, based on trials in Alzheim-
er’s disease. A review in Alzheimer’s disease published 
in 2010 [25] found that a large number of different 
treatments are currently being tested. No less than 13 
Phase III studies were on going with most using tra-
ditional two-arm designs, meaning that equally many 
control groups are being used. Although not all treat-
ments are targeting the same mechanism of actions and 
hence are not immediately comparable, there are still 
three or four treatments being evaluated when only con-
sidering treatments that are targeting the same mecha-
nism of action. In this illustration we will compare the 
sample size requirements of different strategies to evalu-
ate 3 experimental treatments in Alzheimer’s disease. 
The first strategy evaluates all three experimental treat-
ments in three distinct two-arm trials while the second 
utilizes separate group-sequential designs with triangu-
lar stopping boundaries [26]. The third strategy evaluates 
all three experimental treatments in a single study while 
a design with multi-arm with treatment selection of all 
promising treatments [27] is used as the final alternative.
For this hypothetical example, we will use the design 
parameters used in the recently completed LADDER 
trial [28]. The primary end point of interest is the 
change from baseline in the 11-item Alzheimer’s Dis-
ease Assessment Scale–cognitive subscale [29] at week 
24 and we model the outcome as normally distributed. 
In line with [28], we assume a standard deviation of 6 
in the primary outcome and that a 2 point difference 
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is considered a clinically relevant effect. A one-sided 
type-I error of 2.5% and power of 90% are used.
Table 1 provides the (maximum) sample sizes of the 
four different strategies to evaluate three experimen-
tal treatments. We consider conducting three separate 
two-armed trials, three group-sequential trials as well 
as multi-arm trials with and without selection and use 
equal allocation of patients to all arms. Calculations 
were performed using the R package MAMS [30]. The 
group-sequential design and the multi-arm trial with 
selection each use one interim analysis conducted at 
the half-way point of the study. As group-sequential 
designs and multi-arm designs with treatment selec-
tion offer the opportunity to stop early, the expected 
sample sizes when no treatment is better than control 
and when exactly one treatment is superior to control 
are also provided. The (maximum) sample size of using 
separate trials to evaluate the experimental treatments 
is larger than the sample size required if a multi-arm 
trial design (with or without selection) is used. This 
is despite the fact that no attempt has been made to 
correct for multiplicity when using separate studies. 
The sample size of three separate single-stage trials 
when using a Bonferroni correction to ensure overall 
type-I-error control – something that the multi-arm 
designs discussed here do provide automatically – is 
at 1464 patients, about 50% larger than the multi-
arm strategies. When acknowledging that a multi-arm 
design with treatment selection is expected to drop at 
least some arms, we find the advantage of the multi-
arm design to be even larger. With only around 640 
patients expected to be required before a definitive 
conclusion is reached, a multi-arm strategy is clearly 
more efficient than conducting separate studies.
Practical considerations for multi-arm 
studies
Clearly there is a substantial efficiency advantage 
in using a multi-arm study with treatment selection 
instead of conducting several separate trials. The above 
arguments, though statistically correct, are however 
a little bit over-enthusiastic. This is because some 
additional considerations and administrative hurdles 
need to be overcome to benefit from these, potentially 
large, gains. First there are considerations that come 
from the desire to evaluate several experimental treat-
ments against a common control and second there are 
considerations that only apply because interim analy-
ses are used for treatment selection. The latter are by 
large similar to challenges encountered in two-arm 
group-sequential designs.
The first challenge introduced by comparing mul-
tiple arms is that different trials comparing a single 
treatment against control are often initiated and con-
ducted by different centres. As a result, they have dif-
ferent inclusion and exclusion criteria, may use differ-
ent primary and secondary end points and possibly a 
different comparator treatment. All of these must be 
standardized for a multi-arm trial that requires nego-
tiations and compromises between investigators. Since 
a multi-arm trial operates as a single trial under one 
protocol all treatments in the study need to be available 
at the same time to ensure contemporary evaluation. 
Additionally, a multi-arm study implicitly assumes 
that all experimental treatments start at an equal foot-
ing and hence they will only be efficient if there is no 
reason to believe that one treatment will have a better 
chance of yielding an improvement over control than 
any other.
A second challenge is to ensure that no bias in the 
evaluation is introduced in multi-center multi-arm 
studies through imbalances between allocations to 
treatments at different centers/regions. It is therefore 
paramount that randomization to all arms (includ-
ing the control arm) is stratified by center or region to 
ensure that the risk of bias is minimized.
The third challenge concerns the analysis of such 
studies. At the end of a multi-arm study estimating 
the effect of the best experimental treatment is often 
of main interest. Using standard analysis methods 
for this purpose will result in an over-enthusiastic 
(upward biased) estimate of the effect [31]. Specialized 
methods that lead to unbiased estimators [31] or reduce 
the bias [32] are therefore necessary for analyzing such 
Table 1. Sample size requirement for different strategies to evaluate three experimental Alzheimer’s treatments 
against control
Design option Maximum sample size Expected sample size
All treatments ineffective One treatment effective
Three separate two-armed trials 1140 1140 1140
Three separate group-sequential trials 1296 788.54 884.88
Multi-arm study without selection 952 952 952
Multi-arm study with treatment 
selection
1048 642.51 642.88
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studies. Similarly, specialized methods to construct 
confidence intervals are required [33,34].
The first important consideration when allowing 
interim analyses for treatment selection is that the 
maximum sample size required will be larger than 
for a multi-arm study without selection (although 
the expected number of patients is typically nota-
bly smaller). Even though the increase in maximum 
sample size is typically small, recruiting the maxi-
mum number of patients still needs to be possible 
and investigators need to be prepared to recruit 
that many patients in the unlikely event that no 
treatment can be dropped early and no early claim of 
superiority is possible.
Second, in order to observe (notable) reductions 
in the sample size required, the end point utilized for 
treatment selection (typically the primary end point 
or some short-term surrogate) needs to be available 
quickly relative to the recruitment rate. The reason 
for this is that patients will continue to be random-
ized to each arm while the data to make the interim 
treatment selection are being collected. In the most 
extreme case therefore all patients could already be 
recruited by the time the information from assessed 
patients is available for making the treatment 
selection decision.
Third, the organization of interim analyses must 
be efficient with data monitoring and statistical 
analysis done to tight deadlines as delays in the selec-
tion decision reduces the benefit of such a design as 
argued above. Additional resource may therefore be 
required to allow a quick decision making as well as 
ensuring blinding and trial integrity is maintained. 
To achieve this, efficient communication between 
the investigators, data management and statisticians 
is essential.
A fourth consideration is around communicating 
the more complex design of a multi-arm study with 
treatment selection to both patients and investiga-
tors. In particular, the informed consent procedure 
requires careful consideration as patients need to be 
fully aware of all possibilities. In the STAMPEDE 
trial, for example, a two-part patient information 
sheet was used. Information on all arms was provided 
to all patients while further details on the allocated 
arms were made available after randomization [35].
The final challenge concerns planning and ensur-
ing treatment supply. The maximum drug supply is 
uncertain as arms can be stopped prior to the end 
of the study. Although the same issue is present in 
group-sequential designs, the additional arms make 
this challenge more pronounced in multi-arm stud-
ies with treatment selection. Accurate planning 
and in particular precise estimation of recruitment 
rates – particularly for multi-center studies 
(e.g., [36]) – are paramount.
Discussion
Multi-arm studies with treatment selection are an 
efficient means for drug development when sev-
eral potentially useful treatments are available for 
testing, and a number of different studies are now 
being run under this framework in a variety of dis-
ease areas [37–39]. In this paper, we have not only 
highlighted the potential gains that are possible 
when using such an approach but also discussed 
the additional complexities such designs bring with 
them. While we have kept the illustration simple, 
it should be noted that in-depth evaluations of the 
design alternatives, usually via simulations, are cru-
cial when deciding which design is best. To support 
the implementation of these ideas, various software 
solutions exist. Commercial software such as Add-
Plan [40] or EAST [41] provide tools to design, simu-
late and analyze such studies. Additionally, the add-
on packages MAMS [30] and asd [42] for the statistical 
software R [43] are freely available.
Future perspective
Multi-arm designs will become more widely used in 
the future as an efficient tool to make evidence-based 
decisions about different licensed treatments. Addi-
tionally, their use during the development of novel 
treatments will increase as familiarity with these 
ideas rises.
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Executive summary
•	 Multi-arm designs are an efficient way to evaluate multiple experimental treatments.
•	 Allowing for selection of treatments enables even bigger gains in efficiency.
•	 Additional considerations and operational hurdles apply that mean that planning of such studies is more 
complex and time consuming.
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